Does macitentan reduce morbidity and mortality in patients with pulmonary arterial hypertension?
Macitentan significantly reduces morbidity and mortality in patients with pulmonary arterial hypertension.
Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).
Pulido et al. (Wed,) studied this question.